Company profile: Linnaeus Therapeutics
1.1 - Company Overview
Company description
- Provider of development-stage cancer therapeutics, including LNS8801, an orally bioavailable, highly specific G protein-coupled estrogen receptor (GPER) agonist that depletes c-Myc protein levels, shows antitumor activities in preclinical cancer models, and is being tested in clinical trials as a monotherapy and with pembrolizumab.
Products and services
- LNS8801: An orally bioavailable, clinical-stage, highly specific GPER agonist that depletes c-Myc protein, shows antitumor activity in preclinical cancer models, and is tested alone and with pembrolizumab
- Oncology Drug Development and Commercialization: Develops and commercializes cancer drugs, including LNS8801, with activities spanning preclinical antitumor modeling and clinical testing, development-stage
- Clinical Trials for LNS8801: Executes clinical evaluations of LNS8801 as monotherapy and alongside pembrolizumab in cancer indications, advancing from preclinical antitumor models, GPER-targeted
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Linnaeus Therapeutics
Freenome
HQ: United States
Website
- Description: Provider of blood-based tests and clinical studies for early cancer detection to improve access to routine screening, including PREEMPT CRC for colorectal cancer and the PROACT LUNG study using a blood test. Runs the Vallania and Sanderson studies targeting multiple cancers, pairing real-world data with multiomics; partners with Walgreens to increase research diversity; and acquired Oncimmune Ltd to enhance its cancer detection portfolio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Freenome company profile →
Precipio
HQ: United States
Website
- Description: Provider of cancer diagnostics and personalized medicine, offering hematopathology clinical diagnostic services and SmartPath second-opinion services for treatment plan validation, molecular testing reagents including HemeScreen, Bloodhound BCR-ABL1, and HemeScreen AML, and IV-Cell culture media for multi-cell lineage with simplified workflow and clinical accuracy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precipio company profile →
Immunovia
HQ: Sweden
Website
- Description: Provider of blood-based diagnostics for early detection of pancreatic cancer, conducting clinical trials and validation studies to ensure accuracy and reliability, and collaborating with medical institutions and research centers globally to validate its diagnostic tests and bring them to market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovia company profile →
Checkpoint Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology and targeted oncology therapies in development, advancing a pipeline including cosibelimab (fully human anti-PD-L1 monoclonal antibody), olafertinib (oral third-generation irreversible EGFR inhibitor for NSCLC), CK-103 (BET bromodomain inhibitor), CK-302 (agonistic GITR antibody), and an anti-CAIX antibody for renal cell carcinoma, plus product purchases, in-licensing and co-development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Checkpoint Therapeutics company profile →
OncoQuest
HQ: Canada
Website
- Description: Provider of biopharmaceutical products and services, based in Edmonton.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoQuest company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Linnaeus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Linnaeus Therapeutics
2.2 - Growth funds investing in similar companies to Linnaeus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Linnaeus Therapeutics
4.2 - Public trading comparable groups for Linnaeus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →